Quick Answer
Kalaris Therapeutics, Inc. reported Operating Income of -$46.15 million for fiscal year 2025.
Kalaris Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$46.15M | +10.8% |
| 2024 | -$51.73M | +74.1% |
| 2023 | -$199.90M | -16.8% |
| 2022 | -$171.20M | -0.8% |
| 2021 | -$169.82M | -138.1% |
| 2020 | -$71.31M | -167.1% |
| 2019 | -$26.70M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$12.74M | +66.3% | -4.0% |
| June 30, 2025 | -$12.26M | -192.7% | -18.4% |
| March 31, 2025 | -$10.35M | -304.0% | +72.6% |
| September 30, 2024 | -$37.85M | +19.4% | -804.0% |
| June 30, 2024 | -$4.19M | +91.1% | -63.4% |
| March 31, 2024 | -$2.56M | +94.1% | +94.5% |
| September 30, 2023 | -$46.96M | -9.3% | +0.7% |
| June 30, 2023 | -$47.30M | -6.0% | -9.4% |
- Kalaris Therapeutics, Inc. showed an increase of +10.8% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Kalaris Therapeutics, Inc.’s operating income has declined by 72.8% (from -$26.70 million to -$46.15 million).
- The most recent figure is from Kalaris Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: